| 000 | 02564nam a2200313Ia 4500 | ||
|---|---|---|---|
| 003 | MX-MdCICY | ||
| 005 | 20250625160141.0 | ||
| 040 | _cCICY | ||
| 090 | _aB-15924 | ||
| 245 | 1 | 0 | _aHigh-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR) |
| 490 | 0 | _vNature Methods, 4(5), p.1051-1057, 2007 | |
| 520 | 3 | _aIntegrating vector systems used in clinical gene therapy have proven their therapeutic potential in the long-term correction of immunodeficiencies. The integration loci of such vectors in the cellular genome represent a molecular marker unique for each transduced cell and its clonal progeny. To gain insight into the physiology of gene-modified hematopoietic repopulation and vector-related influences on clonal contributions, we have previously introduced a technology-linear amplification-mediated (LAM)PCR-for detecting and sequencing unknown DNA flanking sequences down to the single cell level (Supplementary Note online). LAM-PCR analyses have enabled qualitative and quantitative measurements of the clonal kinetics of hematopoietic regeneration in gene transfer studies, and uncovered the clonal derivation of non-leukemogenic and leukemogenic insertional side effects in preclinical and clinical gene therapy studies. The reliability and robustness of this method results from the initial preamplification of the vector-genome junctions preceding nontarget DNA removal via magnetic selection. Subsequent steps are carried out on a semisolid streptavidin phase, including synthesis of double complementary strands, restriction digest, ligation of a linker cassette onto the genomic end of the fragment and exponential PCR(s)with vector- and linker cassette-specific primers. LAM-PCR can be adjusted to all unknown DNA sequences adjacent to a known DNA sequence. Here we describe the use of LAM-PCR analyses to identify 5' long terminal repeat (LTR)retroviral vector adjacent genomic sequences (Fig. 1 and Box 1). | |
| 650 | 1 | 4 | _aDNA |
| 650 | 1 | 4 | _aMOLECULAR MARKER |
| 650 | 1 | 4 | _aRETROVIRUS VECTOR |
| 650 | 1 | 4 | _aSTREPTAVIDIN |
| 700 | 1 | 2 | _aSchmidt, M. |
| 700 | 1 | 2 | _aSchwarzwaelder, K. |
| 700 | 1 | 2 | _aBartholomae, C. |
| 700 | 1 | 2 | _aZaoui, K. |
| 700 | 1 | 2 | _aBall, C. |
| 700 | 1 | 2 | _aPilz, I. |
| 700 | 1 | 2 | _aBraun, S. |
| 700 | 1 | 2 | _aBraun, S. |
| 700 | 1 | 2 | _aVon Kalle, C. |
| 856 | 4 | 0 |
_uhttps://drive.google.com/file/d/1YR75gpkSKlqOKg61v6GhkdcVpVxyjIqH/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx |
| 942 |
_2Loc _cREF1 |
||
| 008 | 250602s9999 xx |||||s2 |||| ||und|d | ||
| 999 |
_c50100 _d50100 |
||